The value of anti-CD30 CAR T cells in Hodgkin lymphoma
The use of chimeric antigen receptor (CAR) T cells in haematological malignancies is becoming increasingly widespread, with several authorised drugs and many patients benefiting from their efficacy and manageable tolerance in the short and medium term.